Acylhydrazone derivatives of the formula (I) are SGK inhibitors and can be used for the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in any type of fibrosis and inflammatory process. In which R.sup.1, R.sup.5 each, independently of one another, H, OH, OA, OAc or methyl, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10 each, independently of one another, H, OH, OA, OAc, OCF.sub.3, Hal, NO.sub.2, CF.sub.3, A, CN, OSO.sub.2CH.sub.3, SO.sub.2CH.sub.3, NH.sub.2 or COOH, R.sup.11H or CH.sub.3, A alkyl having 1, 2, 3 or 4 C atoms, X CH.sub.2, CH.sub.2CH.sub.2, OCH.sub.2 or --CH(OH)--, Hal F, Cl, Br or I.